New heart drug mavacamten tested in japanese patients

NCT ID NCT07541833

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a drug called mavacamten in adults with a type of heart disease called obstructive hypertrophic cardiomyopathy (HOCM) in Japan. The goal is to see if mavacamten can improve heart function and symptoms when added to their current treatment. About 36 participants will be followed to check safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavacamten
What this could lead to: If successful, this could provide a new treatment option for people with obstructive hypertrophic cardiomyopathy in Japan, potentially improving heart function and daily symptoms.
What could go wrong: This is a small, early-phase study with only 36 participants, so results may not apply to everyone. The drug may cause side effects or not work as well as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMYOPATHY

Contacts and locations

Locations

Mebix. Inc
RECRUITING

Minato-ku, Tokyo, 1050001, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.